Sprint Bioscience AB (OSTO:SPRINT) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:SPRINT Sprint Bioscience AB OSTO:SPRINT
22 GF Score
Price kr3.66
! 1 Warning Sign
View Full Analysis

What is Sprint Bioscience AB Net Loan?

Net Loan only applies to banks and insurance companies.

OSTO:SPRINT
22GF Score
Sprint Bioscience AB OSTO:SPRINT
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sprint Bioscience AB Business Description

Other Exchanges 5JA1:Germany
Address Halsovagen 7, floor 8, elevator A, Novum, Huddinge, SWE, 141 57
Sprint Bioscience AB is a pharmaceutical company focused on developing drug candidates that can contribute to new treatments for cancer. Its product portfolio includes VRK1, VPS34, PETRA01, TREX1, NNMT, STK25, and DCPS. The company receives revenue for out-licensing drug programs, which include the development of a drug candidate.
22GF Score

Get the complete analysis for OSTO:SPRINT

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr3.66
Price